Affordable Access

[Daclizumab and basiliximab: monoclonal mouse-man antibodies with effective immunosuppression without side effects].

Authors
  • ter Meulen, C G
  • Hilbrands, L B
  • van Riemsdijk-van Overbeeke, I C
  • Hené, R J
  • Christiaans, M H
  • Hoitsma, A J
Type
Published Article
Journal
Nederlands tijdschrift voor geneeskunde
Publication Date
Dec 09, 2000
Volume
144
Issue
50
Pages
2396–2400
Identifiers
PMID: 11145094
Source
Medline
License
Unknown

Abstract

Four major double-blind randomized trials in kidney transplant patients have shown that the interleukin-2 receptor (IL-2R alpha) antagonists declizumab or basiliximab, when added to an immunosuppressive regimen consisting of cyclosporin and prednisone, reduce the incidence of acute rejections after kidney transplantation by 30-40%, during the first 6 months. Daclizumab and basiliximab are monoclonal antibodies of which the variable parts are of mouse origin and the other components of human origin. The addition of the interleukin-2 receptor antagonists was not accompanied by extra side effects. Ongoing clinical trials aim at answering the question whether the addition of daclizumab and basiliximab will allow to avoid or decrease the use of more toxic immunosuppressive drugs.

Report this publication

Statistics

Seen <100 times